# Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA)

> **NCT01295294** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 187 (actual)

## Conditions studied

- Uterine Hemorrhage

## Interventions

- **DRUG:** Tranexamic acid
- **DRUG:** Mefenamic acid
- **DRUG:** Placebo
- **DRUG:** Mirena (Levonorgestrel IUS, BAY86-5028)

## Key facts

- **NCT ID:** NCT01295294
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2014-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01295294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01295294, "Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01295294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*